Evidence map›Paper›PMID 39678495›Full record

ArticleFrontiers in oncology2024

Commissioning a clinical proton pencil beam scanning beamline for pre-clinical ultra-high dose rate irradiations on a cyclotron-based system.

Jatinder Saini, Danielle P Johnson Erickson, François Vander Stappen, Matt Ruth, Sunan Cui, Vanessa Gorman, Séverine Rossomme, Ning Cao, Eric C Ford, Juergen Meyer and 6 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Epigenomic landscape of nasopharyngeal carcinoma.Medical oncology (Northwood, London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jatinder SainiDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Danielle P Johnson EricksonDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
François Vander StappenProton Therapy - Research and Development, Ion Beam Applications, Louvain-La-Neuve, Belgium.
Matt RuthDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Sunan CuiDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Vanessa GormanProton Therapy - Research and Development, Ion Beam Applications, Louvain-La-Neuve, Belgium.
Séverine RossommeProton Therapy - Research and Development, Ion Beam Applications, Louvain-La-Neuve, Belgium.
Ning CaoDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Eric C FordDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Juergen MeyerDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Charles BlochDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Tony WongDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Clemens GrassbergerDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Ramesh RenganDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Jing ZengDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.
Marco SchwarzDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This manuscript describes modifications to a pencil beam scanning (PBS) proton gantry that enables ultra-high dose rates (UHDR) irradiation, including treatment planning and validation. Methods: Beamline modifications consisted of opening the energy slits and setting the degrader to pass-through mode to maximize the dose rate. A range shifter was inserted upstream from the isocenter to enlarge the spot size and make it rotationally symmetric. We measured the beamline transport efficiency and investigated the variation in output due to the recombination of charge in the dose monitoring chamber. The output calibration was performed through a parallel plate chamber (PPC05), and an intercomparison was performed for various detectors. The pre-clinical field for mice irradiation consisted of different dose levels to deliver uniform doses in transmission mode. The field dose rates were determined through log files while scripting in TPS was used to estimate PBS dose rates. The survival experiments consisted of irradiating the full pelvis of the mice at UHDR and conventional dose rates. Results: The spot size was constant with beam current and had a sigma of 8.5 mm at the isocenter. The beam output increased by 35% at 720 nA compared to 5.6 nA, primarily due to recombination in the dose-monitoring ion chambers. The Faraday Cup and PPC05 agreed within 2%, while other detectors were within 3% of FC for dose rates <60 Gy/s. The pre-clinical fields' PBS dose rate is above 45 Gy/sec for all voxels within the target volume. The average and PBS dose rates decrease as field size increases and approaches 40 Gy/s for a field size of 7x7 cm Conclusions: We successfully modified a clinical system to perform UHDR pre-clinical experiments. As part of our pre-clinical experiments, we observed the FLASH effect concerning mice survival.

Indexed as

FLASHpencil beam scanningpre-clinicalprotonsultra-high dose rate

Identifiers

PMID39678495
PMCPMC11638781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.